Blood Podcast

Blood Podcast

O podcaście

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
359
Odcinki
English
Język
0
Subskrybenci
0
Odsłuchania
Odcinki25
Novel Treatment Targets for Hemophilia A and AML

Novel Treatment Targets for Hemophilia A and AML

Dec 25, 2025·

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better...

Novel Differentiation Therapies for AML and Prognostic Value of PET in MM

Novel Differentiation Therapies for AML and Prognostic Value of PET in MM

Dec 18, 2025·

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this...

Review Series on Platelet Heterogeneity

Review Series on Platelet Heterogeneity

Dec 11, 2025·

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai. Find the full review series in...

Special Episode: Maternal Health in Hematology

Special Episode: Maternal Health in Hematology

Dec 5, 2025·

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health...

Analysis of IELSG37 Trial Results and PF4 in Stem Cell Aging

Analysis of IELSG37 Trial Results and PF4 in Stem Cell Aging

Dec 4, 2025·

In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where...

Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCT

Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCT

Nov 27, 2025·

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter...

Advancing Blood Disorder Treatments Through Precision Therapeutics

Advancing Blood Disorder Treatments Through Precision Therapeutics

Nov 20, 2025·

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new...

New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials

New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials

Nov 13, 2025·

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic...

Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

Nov 6, 2025·

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific...

Review Series on Follicular Lymphoma

Review Series on Follicular Lymphoma

Oct 30, 2025·

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of...

Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms

Breakthroughs in Multiple Myeloma Treatment and Von Willebrand Disease Mechanisms

Oct 23, 2025·

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents...

Spotlight on Acute Myeloid Leukemia

Spotlight on Acute Myeloid Leukemia

Oct 16, 2025·

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “ The fit older adult with acute myeloid...

Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments

Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments

Oct 14, 2025·

In this week's episode we’ll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data...

How I Treat Wiskott-Alrich syndrome

How I Treat Wiskott-Alrich syndrome

Oct 2, 2025·

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal " How I treat Wiskott-Alrich syndrome ". They highlight recent updates in...

Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas

Use of Marstacimab for Prophylaxis in hemophilia A and B; matched-donor allogeneic CD19 CAR-T in adult B-ALL; a new prognostic index for T-cell cutaneous lymphomas

Oct 2, 2025·

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody...

Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma

Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma

Sep 25, 2025·

In this week's episode, we’ll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and...

Review Series on Acute Lymphoblastic Leukemia (ALL)

Review Series on Acute Lymphoblastic Leukemia (ALL)

Sep 18, 2025·

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative...

Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML

Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML

Sep 18, 2025·

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be...

Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations

Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations

Sep 11, 2025·

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not...

“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA

“Ironing out” Tet2-mutant HSPCs; A CAR-T “license to kill” in T cell leukemia/lymphoma; insights on cHL genetics, through the lens of ctDNA

Sep 4, 2025·

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating...

Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD

Targeting NPM1 in AML with a menin inhibitor; in primates, a CD137 ADC eliminates acute GVHD

Aug 28, 2025·

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This...

How I Treat Series on Iron Overload in Hematologic Disorders

How I Treat Series on Iron Overload in Hematologic Disorders

Aug 28, 2025·

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, " How I manage iron overload in the hematopoietic cell transplantation setting " which is featured in Blood's "How I Treat Series on Iron...

Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era

Early prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor era

Aug 21, 2025·

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress...

Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemia

Exogenous CD19 stimulation in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy, sequential rapid immune-assay in heparin-induced thrombocytopenia diagnosis, and new survival prediction models for chronic myelomonocytic leukemia

Aug 19, 2025·

In this week's episode, we’ll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate...

How I Treat series on Acute Myeloid Leukemia

How I Treat series on Acute Myeloid Leukemia

Aug 14, 2025·

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML)...

Może ci się też spodobać